The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

##STR00001##

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

##STR00001##

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. ##STR00001## The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. ##STR00001## The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.

Provided is an organic electrolyte solution that includes a lithium salt, an organic solvent, and a sulfonate ester-based compound represented by Formula 1:

R.sub.2—O—S(═O).sub.2—R.sub.1  <Formula 1> wherein, in Formula 1, R.sub.1 may be a C1-C20 alkyl group that is unsubstituted or substituted with halogen, a C5-C20 cycloalkyl group that is unsubstituted or substituted with halogen, a C6-C40 aryl group that is unsubstituted or substituted with halogen, or a C2-C40 heteroaryl group that is unsubstituted or substituted with halogen, and R.sub.2 may be a substituted or unsubstituted cyclic sulfone group.

Disclosed is an additive for nonaqueous electrolyte solutions, including a compound represented by Formula (1a) or (1b).

In Formulae (1a) and (1b), Z represents a monovalent group represented by Formula (2a), (2b), or (2c).

##STR00001##

##STR00002##

Provided is a lithium secondary battery, which comprises: an electrolyte comprising a non-aqueous organic solvent, a lithium salt, and an additive represented by Chemical Formula 1; a cathode comprising a cathode active material including a Si-carbon composite; and an anode comprising an anode active material.

Provided is a lithium secondary battery, which comprises: an electrolyte comprising a non-aqueous organic solvent, a lithium salt, and an additive represented by Chemical Formula 1; a cathode comprising a cathode active material including a Si-carbon composite; and an anode comprising an anode active material.

The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.

The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.